Sign in Subscribe
United Kingdom

Teva Pharmaceutical Industries Announces Copaxone's Approval in the U.K. for Relapsing-Remitting Multiple Sclerosis

Strategic Insights

— 2 min read

Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) has announced that Copaxone(R) (glatiramer acetate for injection) has been recommended for approval in the U.K. for the treatment of relapsing-remitting multiple sclerosis (RR MS). The Licensing Authority in the U.K. has reviewed the vast scientific and clinical evidence supporting Copaxone's efficacy in reducing the frequency of relapses in patients with RR MS. This approval marks a significant milestone for Teva, as it will enable the company to initiate the European mutual recognition procedure, paving the way for Copaxone's availability in the remainder of the European Union. Teva has worked closely with the U.K. authorities to achieve this goal, and the company is now poised to make Copaxone a widely accepted first-line therapy and the drug of choice for patients who do not benefit or cannot tolerate beta-interferon.

Key Takeaways:

  • The Licensing Authority in the U.K. has recommended the approval of Copaxone(R) for the treatment of relapsing-remitting multiple sclerosis (RR MS), marking a significant breakthrough in the fight against the disease.
  • The approval is based on the growing body of scientific and clinical evidence supporting Copaxone's efficacy in reducing the frequency of relapses in patients with RR MS.
  • With the approval, Teva will initiate the European mutual recognition procedure to make Copaxone available in the remainder of the European Union.
  • Teva has worked closely with the U.K. authorities to achieve this goal, demonstrating the company's commitment to bringing innovative treatments to patients.
  • Copaxone is poised to become a widely accepted first-line therapy and the drug of choice for patients who do not benefit or cannot tolerate beta-interferon.
  • Commenting on the approval, Prof. Lance Blumhardt of Queen's Medical Centre, U.K., stated that "Glatiramer acetate, with its proven clinical benefits and excellent patient tolerability, represents a significant addition to treatment options for people with RRMS."

Statistics:

  • 150,000: The number of relapsing-remitting patients in the E.U. who may benefit from Copaxone.
  • 18: The number of countries where Copaxone is currently approved.
  • 80%: The percentage of Teva's sales that are outside Israel.
  • 2001: The expected year for Copaxone's launch in the E.U. following the completion of the European mutual recognition procedure.

Sources:

  • Teva Pharmaceutical Industries Ltd., "Copaxone(R) Recommended for Approval in the U.K. for the Treatment of Relapsing-Remitting Multiple Sclerosis" (Business Wire, June 2, 2000)
  • "Teva Pharmaceutical Industries Announces Copaxone(R) Recommended for Approval in the U.K. for the Treatment of Relapsing-Remitting Multiple Sclerosis" (Business Wire, June 2, 2000)

Read more